Related Experiment Video

Updated: Apr 5, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.9K

Novel Agents for the Treatment of Type 2 Diabetes

Ralph A DeFronzo, Curtis L Triplitt, Muhammad Abdul-Ghani

    Diabetes Spectrum : a Publication of the American Diabetes Association
    |August 7, 2015
    PubMed

    Insights

    Type 2 diabetes involves multiple defects beyond blood glucose. Novel therapies targeting these combined issues offer promising treatment strategies to delay disease progression.

    Area of Science:

    • Endocrinology
    • Metabolic Diseases
    • Pharmacology

    Background:

    • Type 2 diabetes (T2D) is characterized by impaired insulin secretion, increased hepatic glucose production, and reduced peripheral glucose utilization.
    • Additional pathophysiological factors include adipocyte insulin resistance, altered incretin and glucagon secretion, enhanced renal glucose reabsorption, and brain insulin resistance.
    • Current management often focuses on glycemic control, but delaying disease progression is a critical therapeutic goal.

    Purpose of the Study:

    • To review novel therapeutic options for type 2 diabetes.
    • To highlight innovative approaches targeting the multifaceted pathophysiology of T2D.
    • To emphasize the importance of early combination therapy with diverse mechanisms of action.

    Main Methods:

    • Literature review of recent innovative treatment approaches for type 2 diabetes.
    • Analysis of pathophysiological defects in T2D.
    • Examination of therapeutic strategies targeting multiple disease pathways.

    Main Results:

    • Current treatments primarily focus on lowering blood glucose levels.
    • Innovative therapies are emerging that address multiple pathophysiological defects in T2D.
    • Combination therapy with drugs having different mechanisms of action is recommended for optimal management.

    Conclusions:

    • Type 2 diabetes management should aim to delay disease progression and treatment failure.
    • Novel therapeutic strategies targeting the complex pathophysiology of T2D are under investigation.
    • Early initiation of combination therapy is crucial for effective long-term management of type 2 diabetes.

    More Related Videos

    An In Ovo Model for Testing Insulin-mimetic Compounds06:09

    An In Ovo Model for Testing Insulin-mimetic Compounds

    Published on: April 23, 2018

    11.2K
    Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression04:36

    Author Spotlight: Understanding Retinal Vessel Resilience and Disease Progression

    Published on: January 12, 2024

    1.7K

    Related Concept Videos

    Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

    Oral Hypoglycemic Agents: Biguanides and Glitazones

    Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
    962
    Oral Hypoglycemic Agents: Glinides01:06

    Oral Hypoglycemic Agents: Glinides

    Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
    961
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
    1.3K
    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

    Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

    α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
    Acarbose and miglitol are...
    887
    Oral Hypoglycemic Agents: Sulfonylureas01:17

    Oral Hypoglycemic Agents: Sulfonylureas

    Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
    1.7K
    Diabetes: Management and Pharmacotherapy01:15

    Diabetes: Management and Pharmacotherapy

    The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
    Insulin remains the cornerstone of treatment for most patients with type 1 and many...
    1.5K